• Small molecule autophagy enhancer to clear alpha-synuclein Aggregation of alpha-synuclein is considered the primary cause of dopaminergic, and other cell type, degeneration in PD
  • Potential in other synucleinopathy, e.g. dementia with Lewy bodies (DLB) and multi-system atrophy (MSA)
  • In rodent models of PD, clears alpha-synuclein aggregations and provides both behavioural recovery and cellular protection from damage.
  • Generally Regarded As Safe (GRAS) designated compound
  • Already approved for human use as a food substance
  • Could be rapidly progressed into proof-of-concept clinical studies
  • Potential to launch as a Medical Food after efficacy is demonstrated in a Phase II clinical study
  • $1.2M MJFF funding for Parkinson’s programme will complete pre-clinical development in rodents and NHP and define doses to use in clinical studies